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mately 30% of total costs. Effective oral therapies for treatment
of breast cancer could help offset some of these costs in addition
to providing patient beneﬁts such as fewer clinic visits for IV
administration.
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A MARKOV MODEL EVALUATING THE COST-UTILITY OF A 
4D REAL-TIME ELECTROMAGNETIC TRACKING SYSTEM
(CALYPSO® 4D LOCALIZATION SYSTEM WITH BEACON
TRANSPONDERS) IN THE LOCALIZATION OF PROSTATE
TUMORS DURING RADIOTHERAPY
Williams E, Najib MM
AEQUITAS, San Diego, CA, USA
OBJECTIVES: Since accurate tumor localization during radio-
therapy is critical to maximizing therapeutic efﬁcacy while 
minimizing toxicity, the cost-effectiveness of localization tech-
nologies should be investigated. We performed a cost-utility
analysis evaluating the relative advantage of using a real-time 4D
electromagnetic tracking system, the Calypso® 4D Localization
System with Beacon® Transponders (“Calypso® 4D Localiza-
tion System;” Calypso Medical, Seattle, Washington) during
prostate radiotherapy. METHODS: Using decision analysis and
Markov processes, the outcomes of patients localized during
prostate radiotherapy were simulated over ﬁve years and mea-
sured as direct costs from a payer’s perspective and quality-
adjusted life years (QALYs). The clinical pathway for patients
undergoing external beam radiation was modeled via health
states: 1) Time in Treatment, 2) Relapse-Free with Localization,
3) Relapse-Free without Localization, and 4) Deceased. Using
evidence from a prospective clinical trial of the Calypso® 4D
Localization System and published literature, transition states
were modeled for achievement of biochemical no evidence of
disease (bNED) control and biochemical relapse-free survival
(BRFS). Costs and disutilities of radiation-induced toxicities
were included. Post-hoc sensitivity analyses were performed.
RESULTS: Over ﬁve years, patients localized with real-time 4D
electromagnetic tracking gained 2.47 QALYs at $5432/QALY.
Compared to ultrasound, electronic portal imaging devices, or
computed tomography, the real-time 4D electromagnetic track-
ing system yielded superior QALY gains at comparable costs.
Compared to ultrasound, this technology generated 43 addi-
tional quality-adjusted life days and an incremental cost-
effectiveness ratio of $14,053/QALY. Overall, the model was
sensitive to changes in bNED control rates and BRFS. CON-
CLUSION: The real-time 4D electromagnetic tracking system is
cost-effective for target localization during prostate radiother-
apy. However, the current model’s sensitivity to variances in
long-term outcomes warrants collection of rigorous evidence on 
long-term quality of life and tumor control in patients using
localization technologies. Future studies might incorporate
patient registry data, patient-reported outcomes, and follow-up
data from prospective clinical trials.
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OBJECTIVES: Renal cancer represents 1.5% of all tumors
observed in Mexico and they are responsible of high expendi-
tures in the Mexican Health System. The purpose of the study
was to model the economic and health consequences of second-
line treatments (previous failure of cytokine therapies) in adult
patients with metastatic renal cell carcinoma (mRCC) in stages
III and IV from the health care payer’s perspective. METHODS:
A cost—utility analysis was developed using a Markov model-
ing approach. The model simulates costs and quality adjusted
life years (QALYs) gained in a ten-year period among four pos-
sible health states (no new progression, death due to mRCC,
history of new progression and death due to other causes). The
model aimed to compare sunitinib 50 mg/day vs. local best sup-
portive care (BSC) as second-line treatments. Transition prob-
abilities and QALYs of the Markov model were obtained
according to clinical trials previously published in the literature.
Resource use and costs data was obtained from hospital records
at Hospital de Oncología CMN “Siglo XXI” in Mexico City (n
= 80). Both costs and QALYs were discounted using a 5% annual
rate. Probabilistic sensitivity analysis was performed and
tornado diagrams were constructed (±25% on relevant model
variables). RESULTS: Second line treatment with sunitinib
showed the highest QALYs gained per patient (1.32 QALYs) vs.
BSC treatment (0.39 QALYs). Nevertheless, expected health care
costs for sunitinib resulted in US$36,928 and BSC therapies in
US$4103. The incremental cost per QALY gained resulted in
US$35,238. Results were robust to Monte Carlo ﬁrst order sen-
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sitivity analysis (1000 iterations) and one-way sensitivity analy-
ses (tornado diagrams). CONCLUSION: Sunitinib second-line
treatment for patients with mRCC could be the most cost—
effective alternative compared to BSC if international thresholds
apply in Mexico.
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SYSTEMATIC REVIEW OF TREATMENTS/INTERVENTIONS
AND QALY IN BREAST CANCER PATIENTS
Zhan L, Nair R
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OBJECTIVES: Breast cancer is the most common cancer among
women. Several treatments are available, but there is no com-
prehensive overview which covers both treatments and QALY.
The objective of this study was to conduct a systematic review
of the treatments and QALY for breast cancer patients.
METHODS: Electronic, manual, and bibliographic searches of
OVID, EMBase, and PubMed were conducted expanding from
1990 to 12/21/06. Randomized clinical trials evaluating differ-
ent interventions on breast cancer in QALY were included. Breast
cancer and QALY were used as the key words. Among 169 arti-
cles, 15 articles are included for this full-text review. RESULTS:
Hormone therapy, chemotherapy and prophylactic surgery were
three major methods of treating breast cancer. Among these arti-
cles, 56% of them mentioned letrozole and tamoxifen or their
combination therapy, which were targeted for postmenopausal
women with early stage breast cancer. More QALYs were gained
within the range from 0.1 to 0.36 in 5 years’for (i) tamoxifen
followed by letrozole compared with tamoxifen only or (ii) letro-
zle as the ﬁrst line therapy followed by tamoxifen therapy com-
pared with letrozole as the second-line therapy. Moreover,
anastrozole and exemestane also increased QALYs in post-
menopausal with ER (+) breast cancer patients. Capecitabine/
docetaxel and CMF could increase quality-adjusted survival and
relapse-free survival 1.8 and 1.5 years compared with no treat-
ments. Routine postoperative radiotherapy after sector resection
and ancillary dissection or conservative surgery for early-stage
breast cancer women would also gain QALYs compared without
postoperative radiotherapy. CONCLUSION: Very few studies
have been found using QALY to evaluate different interventions
to treat breast cancer patients in the different stages. Patients
should adopt treatments based on their own age and the stage
of breast cancer. Further research on breast cancer interventions
is needed to understand the cost-effectiveness of alternative or
combining treatments in order to establish standard treatments
for breast cancer.
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OBJECTIVES: To compare cost utility of docetaxel chemother-
apy with other neoadjuvant treatment regimens in locally
advanced breast cancer. METHODS: Cost-utility Markov model
from payer perspective (health insurance and patient), using
costs information from published sources and the patient 
lifetime horizon. RESULTS: Four comparisons, CVAP + T
(cyclophosphamide/vincristine/doxorubicin/prednisolone—
1000/1,5/50/40 mg/m2, 4 cycles + docetaxel/prednisolone—
100/100 mg/m2, 4 cycles) vs CVAP ((cyclophosphamide/
vincristine/doxorubicin/prednisolone—1000/1,5/50/40 mg/m2, 4
cycles + 1000/1,5/50/100 mg/m2, 4 cycles), AC + T (doxoru-
bicin/cyclophosphamide—60/600 mg/m2, 4 cycles + docetaxel
100 mg/m2, 4 cycles) vs AC (doxorubicin/cyclophosphamide—
60/600 mg/m2, 4 cycles), AT (doxorubicin/docetaxel—50/75
mg/m2, 4 cycles) vs FAC (ﬂuorouracil/doxorubicin/cyclophos-
phamide—500/50/500 mg/m2, 4 cycles), AT (doxorubicin/
docetaxel—50/75 mg/m2, 6 cycles) vs AC (doxorubicin/
cyclophosphamide—60/600 mg/m2, 6 cycles) were performed.
One randomized clinical trial was included for each comparison.
Average costs of the treatment of locally advanced breast cancer
(including neoadjuvant chemotherapy, surgery, additional radio-
therapy, treatment of adverse events) and treatment effects were
per patient: CVAP + T 40280 PLN/20,507 QALY vs CVAP
11879 PLN/12,576 QALY; AC + T 39924 PLN/20,483 QALY
vs AC 8886 PLN/12,636 QALY; AT 32056 PLN/20,483 QALY
vs FAC 8480 PLN/12,636 QALY; AT 40186 PLN/20,171 QALY
vs AC 6999 PLN/12,452 QALY. ICUR for CVAP + T vs CVAP
comparison was 3580 PLN/QALY. ICUR for AC + T vs AC was
3955 PLN/QALY and ICER 3402 PLN/LYG. ICUR for AT vs
FAC was 3004 PLN/QALY and ICER 2583 PLN/LYG. ICUR for
AT vs AC was 4300 PLN/QALY and ICER 3637 PLN/LYG.
CONCLUSION: Docetaxel regimens are more effective and
more expensive in the neoadjuvant treatment of patients with
locally advanced breast cancer compared with CVAP, AC and
FAC chemotherapies, ICUR range 3004-4300 PLN/QALY.
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OBJECTIVES: To determine drug requirement for treatment
advanced Hodgkin’s disease. METHODS: Drug requirement
was calculated on the basis of data about recommended treat-
ment schemes of Hodgkin’s disease (HD), amount of treatment
courses for one case of HD and average body surface area of
patients with HD. Average body surface area calculated on the
basis of medical documentation of 182 HD patients were treated
in HSC RAMS. Drug requirement in speciﬁed region or public
health institution was calculated based on frequency of advanced
HD in these region or institution (in our case—HSC RAMS).
RESULTS: HD treatment schemes BEACOPP-14 is pharma-
coeconomic dominate alternative (Tolkushin A.G. et al. 2006).
Average body surface area amount to 1.77 ± 0.037 m2. Amount
of treatment courses for one case of HD were 6. Average drug
requirement were 6.90 g or 69 vials in 100 mg of Cyclophos-
phamide, 3.98 g or 8 vials in 500 mg of Dacarbazine, 266 mg or
5 vials in 50 mg of Doxorubicin, 3.19 g or 32 vials in 100 mg of
Etoposide, 106 mg or 7 vials in 15 mg of Bleomycin, 15 mg or
15 vials in 1 mg of Vincristine and 5.95 g or 1.2 thousand tablets
in 5 mg of Prednisolone. Average number of advanced HD
patients in HIT department of HSC RAMS were 20 patients per
year. Average annual drug requirement in HIT department of
HSC RAMS were 138, 159, 106, 637, 142, 297 vials and 23.7
thousand tablets of Cyclophosphamide, Dacarbazine, Doxoru-
bicin, Etoposide, Bleomycin, Vincristine and Prednisolone,
respectively. CONCLUSION: The drug requirement for one case
of advanced Hodgkin’s disease and average annual drug require-
ment in HSC RAMS were determined. If one know average
number of Hodgkin’s disease patients it is possible to determine
amount of drug.
